Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2127 Detection of Bone Metastases at FDOPA-PET in Small-Intestine (si)NET: Prevalence and Associated Factors

Introduction: FDOPA-PET has high sensitivity to detect siNET and associated metastases.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: de Mestier L

Authors: de Mestier L, Deleval N, Hentic O, Palazzo M, Lebtahi R,

Keywords: small intestine NET, bone metastases, PET, FDOPA-PET,

#997 Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET)

Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Keplinger F, Spindelböck W, Kump P, Heber D, Wießpeiner U,

Keywords: neuroendocrine tumor, DOPA-PET, somatostatin receptor scintigraphy, progression,

#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma

Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: De Marinis L

Authors: Lugli F, Fusco A, Bianchi A, Iacovazzo D, Mormando M,

Keywords: malignant pheochromocytoma, 18F-DOPA-PET, MIBG,